SCHEMBL19991900

SCHEMBL19991900

CCCCc1ccc2c(cnn2C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 1/20 0.57
TCF7 P36402 1/20 0.57
MPO P05164 1/20 0.44
CCNC P24863 1/20 0.41
HTR2A P28223 1/20 0.41
CDK8 P49336 1/20 0.41
PASK Q96RG2 1/20 0.41
CDK19 Q9BWU1 1/20 0.41
TRPM5 Q9NZQ8 1/20 0.41
CACNA1H O95180 6/20 0.40
DRD4 P21917 3/20 0.40
SIGMAR1 Q99720 2/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SKP2 Q13309 1/20 0.40
PSMB5 P28074 1/20 0.40
TRPA1 O75762 1/20 0.40
KDM2B Q8NHM5 1/20 0.39
HSD11B1 P28845 1/20 0.39
SMO Q99835 1/20 0.39
CACNA1G O43497 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14402843 0.95 CTNNB1 (0.56) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL8220146 0.90 CTNNB1 (0.59) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL6340738 0.86 CTNNB1 (0.56) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL8179108 0.83 CTNNB1 (0.55) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL13476250 0.82 CTNNB1 (0.58) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL31638220 0.82 CTNNB1 (0.58) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL31638366 0.82 CTNNB1 (0.58) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL13547918 0.79 CTNNB1 (0.51) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL16406917 0.78 CTNNB1 (0.54) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL904751 0.78 CTNNB1 (0.54) CTNNB1TCF7MPOCCNCHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2892899-B1 IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL MYERS SQUIBB CO (US) 2018-03-21 EP disclosed